Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Herantis Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Nanoform and Herantis sign Biologics Proof of Concept Agreement

Details:

Nanoform and Herantis have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s proprietary biological nanoparticle technology.

Lead Product(s): Cerebral Dopamine Neurotrophic Factor

Therapeutic Area: Neurology Product Name: CDNF

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Nanoform

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement December 17, 2020

ASK
US

Upload
your Pipeline Activity

Herantis Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial

Details:

Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson's disease patients, with encouraging biological responses.

Lead Product(s): CDNF

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 25, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY